Sage Therapeutics’ rare disease drug meets main goal in mid-stage study

(Reuters) – Sage Therapeutics said on Tuesday its experimental drug met the main goal of a mid-stage study in patients with a type of rare disease known as Huntington’s disease.

(Reporting by Sriparna Roy in Bengaluru; Editing by Shailesh Kuber)